Bone fortifier dietary supplements

Abstract

To provide bone fortifier dietary supplements with a high osteogenesis promoting effect.SOLUTION: A bone fortifier dietary supplement is characterized by containing as an active ingredient isoflavone, and specific components of plant materials, such as Hordeum vulgare, Ipomoea batatas, Peucedanum japonicum, Pinus, Terminalia, Cocos nucifera, Aristotelia Chilensis, and Brassica oleracea.SELECTED DRAWING: Figure 1

Description

[Technical Field]

[0001] The present invention relates to a bone strengthening agent, and more particularly to a bone strengthening agent containing isoflavones and other specific ingredients as active ingredients. [Background technology]

[0002] In recent years, osteoporosis has been increasing, especially among elderly women. It is believed that osteoporosis is caused by poor intestinal calcium absorption and a decrease in the secretion of female hormones that come with aging.

[0003] On the other hand, soy isoflavones, also known as phytoestrogens, have an estrogen-like effect, promoting bone formation and inhibiting bone resorption (bone destruction).

[0004] Examples of preparations that utilize soy isoflavones include a preparation for preventing periodontal disease that contains soy isoflavone aglycone (see Patent Document 1), a plant fermented extract blend that contains a plant fermented extract and isoflavone (see Patent Document 2), and a bone strengthening agent that contains a milk-derived basic protein fraction and / or a milk-derived basic protein fraction hydrolyzate and soy isoflavone as active ingredients (see Patent Document 3). [Prior art documents] [Patent documents]

[0005] [Patent Document 1] Japanese Patent Application Laid-Open No. 2002-121146 [Patent Document 2] Japanese Patent Application Laid-Open No. 2012-240946 [Patent Document 3] Japanese Patent Application Laid-Open No. 2013-184959 Summary of the Invention [Problem to be solved by the invention]

[0006] An object of the present invention is to provide a bone strengthening agent having a high effect of promoting bone formation. [Means for solving the problem]

[0007] The present inventors have conducted extensive research and studies into the bone-strengthening ability of isoflavones, and have found that a high bone formation promoting effect can be obtained by combining isoflavones with specific other components, leading to the completion of the present invention. That is, they have found that the bone formation promoting ability can be synergistically improved by combining isoflavones with specific other components that have little or no bone formation promoting ability.

[0008] That is, the present invention relates to a bone-strengthening agent characterized by containing, as active ingredients, isoflavone and at least one component selected from the group consisting of the following (a) to (e): (a) at least one plant material selected from barley, sweet potato, longevity grass, pine, terminalia, coconut palm, maqui berry, and kale; (b) at least one additive selected from reduced maltose and calcium stearate; (c) at least one amino acid selected from asparagine, cysteine, glutamine, glutamic acid, glycine, leucine, lysine, phenylalanine, serine, and valine; and (d) a polyphenol consisting of chlorogenic acid. (e) At least one vitamin or mineral selected from vitamin B1, vitamin B2, vitamin B6, vitamin B12, sodium pantothenate, niacin, folic acid, vitamin K, magnesium, iron, selenium, and calcium.

[0009] The bone strengthening agent of the present invention may be obtained by adding an active ingredient comprising isoflavone and at least one component selected from the group consisting of (a) to (e).

[0010] In the bone strengthening agent of the present invention, the blending mass ratio of isoflavone to other active ingredients is preferably in the range of 0.5:1 to 70:1. The bone strengthening agent of the present invention is preferably in the form of a tablet, capsule, powder, granule, or liquid.

[0011] The present invention also relates to a bone strengthening method (excluding medical procedures) which comprises ingesting the bone strengthening agent of the present invention. [Effects of the Invention]

[0012] According to the bone strengthening agent of the present invention, a high bone formation promoting effect can be obtained, and bones can be strengthened. [Brief explanation of the drawings]

[0013] [Figure 1] This figure shows the results of Runx2 gene expression when the bone-strengthening agent of the present invention (isoflavones + plant material) was applied to an osteoblast cell line (MC3T3-E1), and shows, from left to right, cases when barley, sweet potato, chomeisou grass, and pine were used as plant materials. [Figure 2] This figure shows the results of Runx2 gene expression when the bone-strengthening agent of the present invention (isoflavones + plant material) was applied to an osteoblast cell line (MC3T3-E1), and from left to right, shows the cases when Terminalia, coconut palm, and maqui berry were used as plant materials. [Figure 3] This figure shows the results of Runx2 gene expression when the bone-strengthening agent of the present invention (isoflavones + additives) was applied to an osteoblast cell line (MC3T3-E1). The left graph shows the results when reduced maltose was used as an additive, and the right graph shows the results when calcium stearate was used as an additive. [Figure 4] This figure shows the results of Runx2 gene expression when the bone-strengthening agent of the present invention (isoflavones + amino acids) was applied to an osteoblast cell line (MC3T3-E1). The graph on the left shows the results when asparagine was used as the amino acid, and the graph on the right shows the results when cysteine ​​was used as the amino acid. [Figure 5]This figure shows the results of Runx2 gene expression when the bone-strengthening agent of the present invention (isoflavones + amino acids) was applied to an osteoblast cell line (MC3T3-E1). The graph on the left shows the results when glutamine was used as the amino acid, and the graph on the right shows the results when glutamic acid was used as the amino acid. [Figure 6] 1 shows the results of Runx2 gene expression when the bone-strengthening agent of the present invention (isoflavones + amino acids) was applied to an osteoblast cell line (MC3T3-E1). The graph on the left shows the results when glycine was used as the amino acid, and the graph on the right shows the results when leucine was used as the amino acid. [Figure 7] This figure shows the results of Runx2 gene expression when the bone-strengthening agent of the present invention (isoflavones + amino acids) was applied to an osteoblast cell line (MC3T3-E1). The graph on the left shows the results when lysine hydrochloride was used as the amino acid, and the graph on the right shows the results when phenylalanine was used as the amino acid. [Figure 8]

[0033] Figure 1 shows the results of Runx2 gene expression when the bone-strengthening agent of the present invention (isoflavones + amino acids) was applied to an osteoblast cell line (MC3T3-E1). The graph on the left shows the results when serine was used as the amino acid, and the graph on the right shows the results when valine was used as the amino acid. [Figure 9] FIG. 1 shows the results of Runx2 gene expression when the bone-strengthening agent of the present invention (isoflavone+polyphenol) was applied to an osteoblast cell line (MC3T3-E1), and chlorogenic acid was used as the polyphenol. [Figure 10] This figure shows the results of Runx2 gene expression when the bone strengthening agent of the present invention (isoflavones + vitamins and minerals) was applied to an osteoblast cell line (MC3T3-E1). The graph on the left shows the results when vitamin B1 was used as the vitamin, and the graph on the right shows the results when vitamin B2 was used as the vitamin. [Figure 11]This figure shows the results of Runx2 gene expression when the bone strengthening agent of the present invention (isoflavones + vitamins and minerals) was applied to an osteoblast cell line (MC3T3-E1). The graph on the left shows the results when vitamin B6 was used as the vitamin, and the graph on the right shows the results when vitamin B12 was used as the vitamin. [Figure 12] This figure shows the results of Runx2 gene expression when the bone-strengthening agent of the present invention (isoflavones + vitamins and minerals) was applied to an osteoblast cell line (MC3T3-E1). The graph on the left shows the results when sodium pantothenate was used as the vitamin, and the graph on the right shows the results when niacin was used as the vitamin. [Figure 13] This figure shows the results of Runx2 gene expression when the bone-strengthening agent of the present invention (isoflavones + vitamins and minerals) was applied to an osteoblast cell line (MC3T3-E1). The graph on the left shows the results when folic acid was used as the vitamin, and the graph on the right shows the results when vitamin K was used as the vitamin. [Figure 14] This figure shows the results of Runx2 gene expression when the bone-strengthening agent of the present invention (isoflavones + vitamins and minerals) was applied to an osteoblast cell line (MC3T3-E1), and shows, from left to right, the results when magnesium, iron, and serine were used as minerals. [Figure 15] This figure shows the results of Runx2 gene expression when the bone-strengthening agent of the present invention (isoflavones + vitamins and minerals) was applied to an osteoblast cell line (MC3T3-E1). From left to right, the results show the cases when eggshell calcium, seaweed calcium, and fish calcium were used as minerals. [Figure 16] FIG. 1 shows the results of Runx2 gene expression when the bone-strengthening agent of the present invention (isoflavones + kale) was applied to an osteoblast cell line (MC3T3-E1). DETAILED DESCRIPTION OF THE INVENTION

[0014] The bone strengthening agent of the present invention is characterized by containing, as active ingredients, isoflavones and at least one component (hereinafter sometimes referred to as "other component") selected from the group consisting of the following (a) to (e): The bone strengthening agent of the present invention has a high ability to promote bone formation, strengthens bones through an increase in bone mass, and can thereby prevent and treat osteoporosis.

[0015] [Isoflavone] The isoflavones that are the active ingredients of the bone strengthening agent of the present invention are flavonoid compounds that are abundant in legumes, particularly soybeans, and the isoflavones used in the present invention are preferably soybean isoflavones derived from soybeans. Isoflavones may be aglycones or glycosides. Furthermore, isoflavones may be purified, or may be a mixture with other components of the raw material (e.g., soybeans). Soybean isoflavones are commercially available, and commercially available products can be used.

[0016] [Other ingredients]

[0017] (a) Plant material In the bone strengthening agent of the present invention, it is preferable to use at least one plant material selected from barley, sweet potato, chou-mei-sou, pine, terminalia, coconut, maqui berry, and kale as an active ingredient together with isoflavones.

[0018] These plant materials may be any part of the plant, such as leaves, stems, roots, flowers, fruits, trunks, or branches. In addition to the plant material itself (including dried products), processed plant material products such as crushed products, juice, and extracts can be used. Examples of crushed products include powders and granules. Juices and extracts may be in liquid form, but can also be used as pastes or dry powders. Extracts can be obtained by extraction using an appropriate solvent, and examples of solvents that can be used include water (hot water), ethanol, and aqueous ethanol. These plant materials can be commercially available.

[0019] As barley, two-rowed barley, six-rowed barley, etc. are usable. As the plant material of the present invention, stems and leaves are preferred, and young leaves are particularly preferred.

[0020] Sweet potato refers to a plant belonging to the Convolvulaceae family, commonly known as Ipomoea batatas. There are no particular limitations on the variety of sweet potato, and examples include Suio, Joy White, Koganesengan, Shiroyutaka, Satsuma Starch, and Ayamurasaki. The parts of the plant used as the plant material of the present invention are preferably the stems and leaves, and particularly young leaves.

[0021] Chomeisou is a perennial plant also known as Peucedanum japonicum, belonging to the genus Peucedanum of the family Apiaceae. The leaves and roots are preferred parts to be used as the plant material of the present invention.

[0022] Examples of pine include French maritime pine (Pinus Martima), larch, black pine, red pine, etc., among which French maritime pine (Pinus Martima), which is rich in proanthocyanidins, is preferred. The part used as the plant material of the present invention is preferably bark, and an extract obtained from this pine bark is particularly preferred. This extract contains high concentrations of proanthocyanidins as well as oligomeric proanthocyanidins, and for example, it is preferred that the extract contains 20% by mass or more of oligomeric proanthocyanidins based on the dry mass of the extract.

[0023] Examples of Terminalia include Terminalia bellirica (belerica), Terminalia catappa, Terminalia tomentosa, Terminalia citrina, Terminalia phellocarpa, Terminalia copelandii, Terminalia brassi, Terminalia ivorensis, Terminalia superba, Terminalia arjuna, and Terminalia chebula, and among these, Terminalia bellirica (belerica) and Terminalia chebula are preferred. The part of the plant used as the plant material of the present invention is preferably the fruit.

[0024] Coconut is a plant of the palm family, and the part of the coconut that is used as the plant material of the present invention is preferably the fruit (endosperm).

[0025] Maqui berry is a plant of the Portoceae family native to Patagonia, Chile, and its scientific name is Aristotellia chilensis. The part of the plant used as the plant material of the present invention is preferably the fruit.

[0026] Kale is a plant of the Brassicaceae family, and the parts used as the plant material of the present invention are preferably the leaves and stems. Specifically, dried and crushed kale, dried and powdered kale slurry or squeezed juice, and extracts obtained from kale or its dried products are preferred. Kale that has been subjected to drying, extraction, or other processing immediately after harvest is particularly preferred. If time is required before processing, it is preferable to store the kale using storage methods commonly used by those skilled in the art, such as low-temperature storage, to prevent deterioration. The variety of kale is not particularly limited, and various types of kale can be used, such as kitchen kale, tree kale, bush kale, marrow kale, collard greens, and green-leaf kale.

[0027] (b) Additives In the bone strengthening agent of the present invention, it is preferable to use at least one additive selected from reduced maltose and calcium stearate as an active ingredient together with isoflavone. Reduced maltose and calcium stearate are additives used in the production of tablets, etc., with reduced maltose usually used as an excipient and calcium stearate usually used as a lubricant.

[0028] (c) amino acids In the bone strengthening agent of the present invention, it is preferable to use, together with isoflavones, at least one amino acid (including a salt) selected from asparagine, cysteine, glutamine, glutamic acid, glycine, leucine, lysine, phenylalanine, serine, and valine as an active ingredient. Examples of the salt include sodium salt and hydrochloride.

[0029] (d) Polyphenols In the bone strengthening agent of the present invention, it is preferable to use a polyphenol consisting of chlorogenic acid as an active ingredient together with isoflavone.

[0030] (e) Vitamins and minerals In the bone strengthening agent of the present invention, it is preferable to use, together with isoflavones, at least one vitamin / mineral selected from vitamin B1, vitamin B2, vitamin B6, vitamin B12, sodium pantothenate, niacin, folic acid, vitamin K, magnesium, iron, selenium, and calcium as an active ingredient. Note that iron, selenium, magnesium, and calcium as minerals in the present invention include the form of compounds containing these metals.

[0031] The bone strengthening agent of the present invention is not particularly limited as long as it contains isoflavones and other specified ingredients and can be distinguished from other products in that it is used to strengthen bones. For example, the scope of the present invention includes products that display a bone strengthening effect (osteogenesis promoting effect) on the product itself, packaging, instructions, or promotional materials of the present invention. Examples of such products include so-called health foods such as pharmaceuticals (including quasi-drugs), functional foods such as specified health foods, nutrient-functional foods, and functional food products whose efficacy has been approved by a designated organization, as well as feed. Examples of so-called health foods include those that display claims such as "for maintaining bone health," "for those concerned about bone health," and "preventing bone brittleness."

[0032] Examples of the form of the bone strengthening agent of the present invention include tablets, capsules, powders, granules, liquids, granules, rods, plates, blocks, solids, pills, pastes, creams, caplets, gels, chewable tablets, and sticks. Among these, tablets, capsules, powders, granules, and liquids are particularly preferred. Specific examples include packaged beverages filled in PET bottles, cans, bottles, etc., and instant powdered beverages and instant granular beverages that can be dissolved in water (hot water), milk, fruit juice, green juice, etc. for consumption. These are preferred because they are easy to drink during meals and can be more palatable.

[0033] The bone strengthening agent of the present invention may contain an appropriate amount of isoflavone and other components (active ingredients) within a range that provides the desired effect.

[0034] Generally, when the bone strengthening agent of the present invention is a pharmaceutical or supplement (tablet, capsule), the active ingredient is preferably contained in an amount of 0.01 to 100% by mass, more preferably 0.1 to 85% by mass, and even more preferably 0.5 to 70% by mass, of the total mass converted to dry mass.

[0035] When the bone strengthening agent of the present invention is a packaged beverage (liquid), the active ingredient is preferably contained in an amount of 0.01 to 15 mass % of the total amount, calculated as dry mass, more preferably 0.03 to 12.5 mass %, and even more preferably 0.05 to 10 mass %.

[0036] Furthermore, when the bone strengthening agent of the present invention is an instant powdered drink (powder) or an instant granular drink (granules), the active ingredient is preferably contained in an amount of 0.1 to 80 mass% of the total, calculated on a dry mass basis, more preferably 0.5 to 70 mass%, and even more preferably 1 to 60 mass%.

[0037] To more effectively exert the effects of the present invention, the active ingredient preferably accounts for 80% or more of the total amount of the bone strengthening agent of the present invention (excluding water) in terms of dry mass, more preferably 90% or more, even more preferably 95% or more, and particularly preferably 100%. Furthermore, when the bone strengthening agent of the present invention contains any of components (a) to (e), it is preferable that the contained components consist solely of the active ingredient of the present invention. That is, when the bone strengthening agent of the present invention contains, for example, component (a) (plant material), it is preferable that it does not contain plant materials other than barley, sweet potato, longevity grass, pine, terminalia, coconut, maqui berry, and kale.

[0038] The intake amount of the bone strengthening agent of the present invention is not particularly limited, but from the viewpoint of more significantly exhibiting the effects of the present invention, it is preferable that the daily intake of the active ingredient is 0.1 mg / day or more, more preferably 1 mg / day or more, and even more preferably 10 mg / day or more. The upper limit is not particularly limited, but is, for example, 8 g / day, preferably 4 g / day. In addition, it is preferable that the intake amount of isoflavones by taking the bone strengthening agent of the present invention is 30 mg / day or less (aglycone equivalent).

[0039] The bone strengthening agent of the present invention can be stored as a daily dose in one container or divided into, for example, 2 to 3 containers so that the daily intake amount is the above-mentioned amount.

[0040] The blending mass ratio of isoflavones to other components, calculated on a dry mass basis, is preferably in the range of 0.5:1 to 70:1, more preferably in the range of 0.75:1 to 60:1, even more preferably in the range of 1:1 to 60:1, and particularly preferably in the range of 1:1 to 50:1. When the blending ratio of isoflavones to other components is in the above range, the effects of the present invention can be more effectively exhibited.

[0041] The bone strengthening agent of the present invention can be produced by known formulation methods, adding ingredients other than the orally acceptable active ingredient, as needed.

[0042] Furthermore, examples of the bone-strengthening agent of the present invention include bone-strengthening foods containing the active ingredient, as well as bone-strengthening foods obtained by adding the active ingredient to a food, such as a food that does not normally contain the active ingredient of the present invention to which the active ingredient has been added. The active ingredients may be added separately or simultaneously, or together with other ingredients other than the active ingredient.

[0043] Examples of bone-strengthening foods of the present invention include beverages such as carbonated drinks, nutritional drinks, fruit drinks, lactic acid drinks, smoothies, and green juice; frozen desserts such as ice cream, ice sherbet, and shaved ice; noodles such as soba, udon, harusame, Chinese noodles, and instant noodles; sweets such as candy, candy, gum, chocolate, tablet sweets, snacks, biscuits, jelly, jam, cream, baked goods, and bread; processed seafood and livestock foods such as kamaboko, ham, and sausage; processed milk, fermented milk, Examples include dairy products such as yogurt; oils and fats such as salad oil, tempura oil, margarine, mayonnaise, shortening, whipped cream, dressing, and processed foods thereof; seasonings such as sauces and soy sauce; and retort pouch foods such as curry, stew, oyakodon, rice porridge, porridge, Chinese rice bowl, katsudon, tempura bowl, beef bowl, hayashi rice, omelet rice, oden, mapo dolphin, gyoza, shumai, hamburger steak, meatballs, various sauces, and various soups.

[0044] The bone strengthening method of the present invention is characterized by ingesting the bone strengthening agent of the present invention as described above, but does not include medical procedures. For example, the method of the present invention can be a method of strengthening bones by providing the bone strengthening food of the present invention in a restaurant or other eating and drinking establishment. [Example]

[0045] The present invention will be described below based on examples. [Example 1] 5 × 10 osteoblastic cell line (MC3T3-E1) cells cultured in culture medium (MEMa; Alpha modification of Eagle's Minimum Essential Media, 10% FBS, 1% PS) were added to the 100-well plate. 3 The cells were seeded at a dose of 1 / well onto a 96-well plate.

[0046] Subsequently, 0.1 mL of 0.5 μg / mL isoflavone or a solution containing other components dissolved at the specified concentrations shown in Tables 1 to 5 was added, and the cells were cultured for 48 hours. Runx2 gene expression was measured by real-time PCR (preliminary WST confirmation confirmed that the concentration was such that 90% or more of the cells survived compared to the control). The Runx2 gene is a transcription factor essential for osteoblast differentiation, and is known to induce osteoblast differentiation and promote bone formation.

[0047] The results are shown in Tables 1 to 5 and Figures 1 to 15. Each graph in the figures represents, from left to right, the results of "Control- (no addition)," "Control+ (0.5 μg / mL isoflavone added alone)," "Other components added alone," and "0.5 μg / mL isoflavone + other components added." The numerical values ​​in the legend below the graphs indicate the sample concentration; for example, "250-" for barley in the graph in Figure 1 indicates 250 μg / mL barley. The concentration unit of the added components is μg / mL in all graphs. The graphs are expressed as relative values ​​when the value of Control+ is set to 1.

[0048] [Table 1]

[0049] For barley, dried and ground powder of young leaves was used. For sweet potatoes, dried and crushed young leaves were used. For Chomeisou, dried and crushed powder of leaves was used. For pine, a hot water extract (dried powder) of the bark of French maritime pine was used. For Terminalia, a hot water extract (dried powder) of the fruit was used. For the coconut, commercially available coconut milk was used after drying and removing the oil. For maqui berry, commercially available dried powder of the fruit was used. For kale, dried and crushed powder of leaves was used. For mugwort, finely ground fresh leaves were used.

[0050] [Table 2]

[0051] [Table 3]

[0052] [Table 4]

[0053] [Table 5]

[0054] As shown in Tables 1 to 5 and Figures 1 to 15, the expression level of the Runx2 gene in osteoblast cell lines was synergistically increased by combining isoflavones with the specific other components of the present invention. Therefore, the bone-strengthening agent of the present invention promotes bone formation and effectively strengthens bones.

[0055] [Example 2] (Production of tablets) A mixture consisting of 25 mg of soy isoflavones, 10 mg of aspartame, 50 mg of reduced maltose, 200 mg of calcium stearate, 10 mg of cysteine, 5 mg of lysine hydrochloride, 5 mg of phenylalanine, 0.1 mg of serine, 5 mg of niacin, 0.05 mg of folic acid, 0.1 mg of vitamin K, 0.01 mg of iron, 0.02 mg of magnesium, 50 mg of maqui berry, 0.2 mg of pine bark extract, and 50 mg of fish calcium was compressed into tablets.

[0056] [Example 3] (Production of capsules) A mixture consisting of 50 mg of soy isoflavones, 180 mg of aspartame, 50 mg of reduced maltose, 350 mg of calcium stearate, 10 mg of cysteine, 5 mg of lysine hydrochloride, 5 mg of phenylalanine, 0.1 mg of serine, 5 mg of niacin, 0.05 mg of folic acid, 0.1 mg of vitamin K, 0.01 mg of iron, 0.02 mg of magnesium, 50 mg of coconut, and 0.2 mg of seaweed calcium was enclosed in a soft capsule to produce a capsule preparation.

[0057] [Example 4] (Production of instant powder 1) A powder formulation was prepared by mixing 50 mg of soy isoflavones, 180 mg of aspartame, 200 mg of reduced maltose, 200 mg of maltose, 200 mg of calcium stearate, 250 mg of asparagine, 25 mg of glutamine, 25 mg of glutamic acid, 20 mg of glycine, 20 mg of leucine, 10 mg of chlorogenic acid, 0.1 mg of vitamin B1, 0.1 mg of vitamin B2, 0.1 mg of vitamin B6, 0.05 mg of vitamin B12, 0.05 mg of sodium pantothenate, 0.2 mg of folic acid, 0.1 mg of vitamin K, 2000 mg of indigestible dextrin, 2000 mg of barley leaf powder, 2000 mg of kale powder, 500 mg of finely ground green tea powder, and 250 mg of shellfish calcium. This powder formulation was highly soluble in 100 ml of water.

[0058] [Example 5] (Production of instant powder 2) A powder formulation was produced by mixing 100 mg of soy isoflavones, 1000 mg of reduced maltose, 1200 mg of maltose, 300 mg of sugar, 2000 mg of indigestible dextrin, 250 mg of asparagine, 25 mg of glutamine, 25 mg of glutamic acid, 20 mg of glycine, 20 mg of leucine, 10 mg of chlorogenic acid, 0.1 mg of vitamin B1, 0.1 mg of vitamin B2, 0.1 mg of vitamin B6, 0.05 mg of vitamin B12, 0.05 mg of sodium pantothenate, 0.2 mg of folic acid, 0.1 mg of vitamin K, 2000 mg of young sweet potato leaf powder, 2000 mg of kale powder, 500 mg of finely ground green tea powder, and 10 mg of uncalcined coral calcium. This powder showed good solubility when dissolved in 200 ml of water.

[0059] [Example 6] (Production of a PET bottle liquid) A liquid preparation was produced by filling a plastic bottle with 75 mg of soy isoflavones, 2500 mg of reduced maltose, 350 mg of asparagine, 50 mg of glutamine, 50 mg of glutamic acid, 50 mg of glycine, 20 mg of leucine, 20 mg of valine, 20 mg of chlorogenic acid, 0.2 mg of vitamin B1, 0.2 mg of vitamin B2, 0.2 mg of vitamin B6, 0.2 mg of vitamin B12, 0.1 mg of sodium pantothenate, 0.2 mg of folic acid, 0.1 mg of vitamin K, 2500 mg of young barley leaf powder, 2500 mg of young sweet potato leaf powder, 1000 mg of Chou-mei-so, 50 mg of pine bark extract, 250 mg of Terminalia bellirica, 500 mg of uncalcined coral calcium, and 500 ml of water, and sealing it. [Industrial Applicability]

[0060] The bone-strengthening agent of the present invention has the effect of strengthening bones and can be used as an oral agent, and therefore the present invention is highly industrially useful.

Claims

[Claim 1] A food product characterized by containing isoflavones and at least one plant material selected from barley, sweet potato, chou-mei-sou, and kale (excluding the following (1), (2), and (3)). (1) A food containing kale powder, water-soluble dietary fiber, maltose, green tea powder, sugar, calcium, spirulina, and soybean germ extract. (2) Food containing processed kale, soybean germ extract, spirulina and / or calcium-containing material. (3) Composition containing propolis, kale, or an extract thereof

Images